Back to Newsroom

Debiopharm Group™ Announces Progress in Phase I Single and Multiple Ascending Dose Study of Debio 1450, its Potent Anti-staphylococcal Agent

Lausanne, Switzerland – October 07, 2014 – Debiopharm Group(Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, announced today excellent progress of its Phase I single and multiple ascending dose study of Debio 1450, a highly potent anti-infective agent selectively active against Staphylococcus species, including all known resistant strains such as methicillin‑resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA).

Click here to read more